Roche's IM­pow­er133 of­fers a glimpse at rare progress in fight against small cell lung can­cer

Last sum­mer Roche’s big R&D group at Genen­tech her­ald­ed a break­through with pos­i­tive sur­vival and dis­ease pro­gres­sion da­ta for its front­line study of its check­point con­tender Tecen­triq in small cell lung can­cer — with land­mark re­sults for a field that had long stymied in­ves­ti­ga­tors.

To­day, the phar­ma gi­ant spelled out its spe­cif­ic gains from IM­pow­er133, set­ting a mark at the World Con­fer­ence on Lung Can­cer that oth­ers can start to shoot at.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER